Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review

White, Donna L.; Kanwal, Fasiha; El–Serag, Hashem B.

doi:10.1016/j.cgh.2012.10.001

Cited by 679 publications

(557 citation statements)

References 66 publications

Supporting

Mentioning

508

Contrasting

Unclassified

Order By: Relevance

“…NASH often leads to fibrosis, which can progress to end-stage liver diseases such as cirrhosis and hepatocellular carcinoma (16). Thus, it is important to distinguish NASH from NAFLD for its early management before NASH progresses to end-stage liver disease.…”

Section: Discussionmentioning

confidence: 99%

The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters

Li¹,

Jian-hui²,

Zhang³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: To develop a clinical score for the prediction of nonalcoholic steatohepatitis (NASH) using routine parameters in patients with nonalcoholic fatty liver disease who had abnormal liver function tests and/or fatty liver detected by ultrasonography. Materials and Methods: To identify parameters associated with the presence of NASH by evaluating anthropometric characteristics and routine biomarkers of 82 patients with histologically proven NAFLD and to develop a clinical score for predicting NASH according to the area under the curve of receiver operating characteristics (AUC) of parameters. Results: Four parameters [alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), C-reactive protein (CRP), and apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1) ratio] were significantly linked to NASH. The AUROCs of ALT, GGT, CRP, and ApoB/ApoA1 ratio for the prediction of NASH were 0.829, 0.892, 0.708, and 0.712, respectively. The AUROC of the combined clinical score for the prediction of NASH was 0.904 (95% CI, 0.885-1.002) at a cut-off of 3.8 points with a sensitivity of 90.2%, specificity of 87.0%, positive predictive value of 88.3%, and negative predictive value of 91.5%. Conclusion: In the present study, a clinical score was developed for the noninvasive prediction of NASH; the score was based on a combination of routine biochemical parameters and was useful in distinguishing NASH from NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters

Li¹,

Jian-hui²,

Zhang³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…27,28 A systematic review of the association between NAFLD and risk for HCC done taking into consideration 17 cohort studies (population based, clinic based, natural history) 18 case control studies and 26 case series or case reports, concluded that risk of HCC was limited to NAFLD or NASH cases with cirrhosis. 29 There is no evidence to support surveillance of general NAFLD or NASH cohort without cirrhosis for HCC.…”

Section: Who Is At Risk Of Hepatocellular Carcinomamentioning

confidence: 99%

Surveillance for Hepatocellular Carcinoma

Ramachandran

2014

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…Key risk factors for HCC include liver cirrhosis (typically due to chronic liver disease) and male sex rates of liver cancer in men are two to four times as high as those in women [4]. HCC arises in a background of liver cirrhosis in 80-90% of cases, [5] with the strength of association dependent on the etiology of the liver disease [6].…”

Section: Introductionmentioning

confidence: 99%

Worse Outcomes among African Americans with Liver Cancer: What Might Cause the Disparity?

Ad¹

2017

Austin J Gastroenterol

View full text Add to dashboard Cite

Liver cancer remains an important cause of cancer mortality in the United States. Incidence of hepatocellular carcinoma (HCC), the most common histological cell type of liver cancer, has increased over the past 30 years. The statistics are particularly worrisome for African Americans. Their incidence of HCC far surpasses that of other races, particularly whites. Additionally, mortality for African Americans with HCC is also far worse. In a review of the literature, we found a stepwise progression of variables that may contribute to this observation. African Americans have the highest observed rates of infection with chronic hepatitis and are offered treatment less often for hepatitis C virus. The progression to cirrhosis is slower, which may complicate HCC surveillance. Regardless, they receive surveillance either biochemical or radiographic at a lower rate than patients of other races. Further, African Americans present at a more advanced stage and are referred for curative therapy less often. When African Americans do receive therapy, their outcomes are worse. Additional investigation is warranted as to whether differences in tumor biology may also play a role.

show abstract

Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review

Cited by 679 publications

References 66 publications

The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters

The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters

Surveillance for Hepatocellular Carcinoma

Worse Outcomes among African Americans with Liver Cancer: What Might Cause the Disparity?

Contact Info

Product

Resources

About